OUR VISION
Micregen has developed an award-winning platform technology - Secretomix® - to guide stem cells to produce multi-factorial, 'off-the-shelf’, secretome therapeutic products aimed at addressing underdevelopment conditions and degenerative processes that are the main cause of many diseases.
Developing disease-modifying cell-free treatments that harness the potent combination of stem cell paracrine factors, including miRNA, extracellular vesicles (inc. exosomes), and proteins (e.g. growth factors)
To date, addressing the challenges of diseases driven by tissue degeneration and/or immaturity has proved difficult. Many diseases are marked by complex, progressive cellular and molecular dysfunction, yet current treatment strategies have offered only limited, symptomatic relief.
The solution has required a multi-targeted approach.
Micregen has approached this challenge through its proprietary Secretomix® platform.
Secretomix® encompasses Micregen’s cell-free, stem cell-derived secretomes, produced using our award-winning platform technology and designed to revolutionise regenerative medicine.
Micregen has demonstrated that our leading therapeutic candidate has displayed disease-modifying capabilities through its multi-modal action, modulating critical factors in cellular degeneration, including inflammation, cellular senescence, altered intercellular communication, stem cell exhaustion, and compromised autophagy.
By targeting multiple pathological pathways simultaneously, Micregen believes Secretomix® offers a unique and comprehensive approach to treating complex diseases.
Developing disease-modifying cell-free treatments that harness the potent combination of stem cell paracrine factors, including miRNA, extracellular vesicles (inc. exosomes), and proteins (e.g. growth factors)
To date, addressing the complex challenges of underdevelopment and degenerative conditions has proved difficult. Most current disease treatments focus on a single facet of the condition and often target its symptoms rather than the root cause. As a result, many diseases currently only receive symptomatic treatment, failing to address the underlying mechanisms of disease progression.
Most diseases are the result of continuous cell and molecular changes, affecting tissues or organs, and increasingly deteriorate over time. Complex solutions are required.
We refer to the products that our proprietary platform produces as Secretomix®.
Our research has demonstrated that they display disease modifying capabilities through their multi-modal action, modulating critical factors in cellular degeneration, including inflammation, cellular senescence, altered intercellular communication, stem cell exhaustion and compromised autophagy.
By targeting multiple pathological pathways simultaneously, we believe they offer a unique and comprehensive approach to treating complex diseases.
Stem cell-based therapy is widely regarded as one of the most promising approaches in regenerative medicine. However, research into whole mesenchymal stem cell transplantation therapy has identified limitations to this area of study, with introduced cells often inefficiently engrafting into target tissues. This can lead to unpredictable and inconsistent therapeutic effects at the site of injury or disease. This variability can reduce treatment effectiveness and hinder reproducibility of clinical outcomes. In addition, cell based therapies may also lead to potential risks including graft rejection, graft-versus-host disease, and possible tumour formation.
Research has shown that the paracrine factors secreted from stem cells were mainly responsible for the repair and regeneration of tissue, rather than the whole cell itself. This finding, with further development over two decades, has gained widespread acceptance in published literature.
Micregen’s research focuses on producing multifunctional secretomes from a clonal stem cell line, creating therapeutics that can be potentially used by everyone (allogeneic).
Micregen has created a GMP cell bank that can continually supply characterised and defined stem cells without the need to continually collect fresh tissue from donors. This tackles historical challenges, including product variability and lowers cost.
Secretomix® can be scaled, manufactured consistently, stored long-term without the need for ultra-cold conditions, and administered immediately at the point of care.
Secretomix® offers great potential for regenerative medicine and patient care. Through the secretome’s ability to simultaneously act on numerous cell-signaling pathways, Micregen aims to provide a novel treatment for multiple conditions.
The Secretomix® platform is designed to create various secretome formulations.
Secretomix is a multi-component biologic (Including components like miRNA, Exosomes, Cytokines, Anti-inflammatory Factors, Lipids, and Proteins, including growth factors) that acts to enhance multiple aspects of tissue repair and regeneration, modulating several key mechanisms.
Stem cell secretomes have been proven to stimulate tissue repair, modulate inflammation and scarring, improve blood flow, and generate a pro-regenerative micro-environment across various organs and tissue types (Tran and Damaser 2015, Kusuma, Carthew et al. 2017, Haque N. 2018).
The Extracellular Vesicle (EV) component of Micregen’s product is able to access many areas of the body to facilitate repair and regeneration. Interestingly, certain secretome EVs have been shown to cross the Blood Brain Barrier, providing the potential to treat certain neurological diseases (Ramos-Zaldívar, Polakovicova et al. 2022).
Micregen believes that their innovative approach in developing the Secretomix® platform to produce various optimised secretome formulations from its first GMP master and working cell banks, could change how a number of critical and chronic diseases are managed.